Kontakta oss Sidkarta Disclaimer & Privacy

Beställ särtryck

1. Heise T et al, 2007 Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies
2. Dornhorst A et al, 2008 Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE™ study
3. Russell-Jones D et al, 2007 Insulin-associated weight gain in diabetes – causes, effects and coping strategies
4. Klein O et al, 2007 Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes
5. Philis-Tsimikas A et al, 2006 Comparison of Once-Daily Insulin Detemir with NPH Insulin Added to a Regimen of Oral Antidianetic Drug in Poorly Controlled Type 2 Diabetes
6. Philis-Tsimikas A et al, 2008 (review) An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update)
7. Philis-Tsimikas A et al, 2008 Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes
8. Bartley PC et al, 2008 Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial
9. Braun D et al, 2008 Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes
10. DeVries JH et al, 2007 Refining basal insulin therapy: what have we learned in the age of analogues?
11. Dornhorst A et al, 2008 Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study
12. Rosenstock J et al, 2008 A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
13. Meneghini LF et al, 2008 Insulin detemir: a long-acting insulin analog for the treatment of Type 1 and 2 diabetes
14. Montañana CF et al, 2008 Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients – The PREDICTIVE™ BMI clinical trial
15. Pieber TR et al, 2007 Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy
16. King AB, 2009 Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study
17. Hermansen K et al, 2004 Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes
18. Heise T et al, 2004 Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes
19. Hermansen K et al, 2006 A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naıve People With Type 2 Diabetes
20. Dornhorst A et al, 2008 Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE™
21. Robertson KJ et al, 2007 Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes
22. Blonde L et al, 2009 Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE™ study
23. Asakura T et al, 2009 Evaluation of injection force of three insulin delivery pens

Fyll i nedan för order

Förnamn: *

Efternamn: *

Arbetsplats: *

Adress: *

Postnummer: *

Ort: *

E-post: *

Telefonnummer: *

Verifikationskod: (* anges för att förhindra skräppost)

Senast uppdaterad: 2011-08-03

NovoMix^® 30: Behandling av diabetes mellitus. Injektionsvätska, suspension 100 E/ml. Förpackningar: NovoMix^® 30 FlexPen^® 5 x 3 ml förfylld injektionspenna, NovoMix^® 30 Penfill^® 5 x 3 ml cylinderampull. SPC uppdaterad 10/2009. F, Rx. För pris och vidare information se www.fass.se

Referenser 1. NovoMix^® 30 SPC. 2. Weyer C et al. Diabetes Care 1997; 20(10):1612-4. 3. McSorley PT et al. Clin Ther 2002; 24(4):530-9. 4. Jacobsen LV et al. Eur J Clin Pharmacol 2000; 56(5):399-403. 5. Jang HC et al. Int J Clin Pract 2008; 62(7):1013-8. 6. Nathan DM et al. Diabetes Care 2009; 32(1):193-203. 7. Asakura T et al. Expert Opin Pharmacother 2009; 10(9):1389-93. 8. Rissler J et al. Expert Opin Pharmacother 2008; 9(13):2217-22. 9. Sommavilla B et al. Expert Opin Pharmacother 2008; 9(13):2223-32. 10. Asakura T et al. Curr Med Res Opin 2008; 24(5):1429-34. 11. Hänel H et al. J Diabetes Sci Technol 2008; 2(3):478-81. 12. Rex J et al. Clin Drug Investig 2006; 26(7):367-401. 13. Donsmark M et al. Diabetes Technol Ther 2009; 11(9):581-5. 14. Göke B et al. Diabetes Technol Ther 2005; 7(2):379.